FindTrial
Sign In

Trastuzumab combined with Pertuzumab for Neoadjuvant Treatment of HER2-Positive Breast Cancer: A National Multi-Center Real-World Study

Trastuzumab combined with Pertuzumab for Neoadjuvant Treatment of HER2-Positive Breast Cancer: A National Multi-Center Real-World Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102649
Enrollment
Unknown
Registered
2025-05-18
Start date
2022-08-31
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive breast cancer

Interventions

HER2-positive breast cancer group:None

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis of HER2 positive early breast cancer patients; 2. Accept HP combined with chemotherapy as neoadjuvant therapy; Received HP combined with chemotherapy neoadjuvant therapy at the selected center between January 2019 and December 2021; 4. Patients with at least two complete hospitalization medical records; 5. Patients with complete surgical and neoadjuvant chemotherapy data in their medical records; 6. Complete follow-up data.

Exclusion criteria

Exclusion criteria: 1. Merge patients with other primary malignant tumors; 2.During the period of neoadjuvant therapy, other treatment methods such as TKI, radiotherapy, immunotherapy, etc. are used in combination.

Design outcomes

Primary

MeasureTime frame
Pathologic complete response rate;—

Countries

China

Contacts

Public ContactXiaowei Qi

29 Gaotanyan Main street, Shapingba District, Chongqing

qxw9908@foxmail.com+86 135 2754 5423

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026